57 results
8-K
EX-99.3
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
on which we depend, including delaying or otherwise disrupting our clinical studies and preclinical studies, manufacturing and supply chain, or impairing
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical studies and preclinical studies, manufacturing and supply … chain, or impairing employee productivity; our dependence on third parties in connection with product manufacturing, research and preclinical
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical studies and preclinical studies, manufacturing and supply … chain, or impairing employee productivity; our dependence on third parties in connection with product manufacturing, research and preclinical
8-K
EX-99.1
gplr8it9 c89kz4yw
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
r1agye
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
phn6lf
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.1
u4dsysvjy
7 Nov 23
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
7x69r0tvnc0e
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.2
rydso 0yvp4
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
4ike1qfxi
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
wxk6m43oo0
8 Aug 23
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:01am
8-K
EX-99.1
pw4 xh61daeuwbmga
4 May 23
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
8-K
EX-99.1
jg9q24
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am
8-K
912qfmf1qlagiyw9b
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am